FIG 13.
Examples of advanced hybrid antibiotics undergoing clinical trials: cadazolid (hybrid 17) and TNP-2092, also known as CBR-2092 (hybrid 18). Cadazolid was derived by fusing ciprofloxacin and tedizolid (with overlapping pharmacophores), while TNP-2092 comprises ciprofloxacin and rifampin-derived pharmacophores. These hybrids display limited antibacterial activity against Gram-negative bacilli.